Disease Course in Oncological Patients During Inpatient Rehabilitation and After Three Months Follow-up

Sponsor
Klinik Valens (Other)
Overall Status
Recruiting
CT.gov ID
NCT04842214
Collaborator
(none)
250
1
35.9
7

Study Details

Study Description

Brief Summary

Constant improvements in the areas of diagnostics and treatment lead to an increase of patients surviving an oncological diagnosis ("cancer survivors") thus increasing the cost factor on both society and health care systems. Meta-analysis have shown the effectiveness of multidimensional rehabilitation programs concerning cost-effectiveness and for improving different health parameters. However when submitted to oncological rehabilitation in Switzerland there is no clear definition when to use which specific assessment during the different stages of oncological rehabilitation.

This cohort study aims to evaluate and systematically follow-up patients that are assigned for oncological inpatient rehabilitation at the Rehabilitation Center Walenstadtberg.

The main purposes are i) to evaluate disease onset of oncological patients during rehabilitation and to identify relationships between mobility and cancer-related fatigue at discharge; ii) to identify predictive factors for everyday functioning and social participation after three months discharge.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Oncological Rehabilitation

Study Design

Study Type:
Observational
Anticipated Enrollment :
250 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Evaluation of Disease Course in Oncological Patients During Inpatient Rehabilitation and After Three Months Follow-up: a Cohort Study.
Actual Study Start Date :
Jan 1, 2019
Anticipated Primary Completion Date :
Dec 30, 2021
Anticipated Study Completion Date :
Dec 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Oncologic disorders

All patients assigned for oncological rehabilitation with the diagnosis "Cancer" are included to this cohort.

Behavioral: Oncological Rehabilitation
Multidimensional rehabilitation

Outcome Measures

Primary Outcome Measures

  1. Patient Reported Outcomes Measurement Information System (PROMIS) [Three months (Day 0-Day 92) with time points set after three weeks (Day 21) and three months (Day 92)]

    Change of participants' physical and mental health over three weeks training and after three months discharge (follow-up). The PROMIS Global-10 is a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. The results of the questions are used to calculate two summary scores: a Global Physical Health Score and a Global Mental Health score with higher scores indication better physical and/or mental health.

Secondary Outcome Measures

  1. Multidimensional Fatigue Inventory (MFI) [Three months (Day 0 - Day 92) with time points set after three weeks (Day 21) and three months after discharge (Day 92)]

    Changes of cancer-related fatigue over three training weeks and after three months follow-up. The MFI is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. The scale ranges from 1 to 7 with higher total scores indicating acute levels of fatigue.

  2. Functional Independence Measure (FIM) [Three weeks (Day 0 - Day 21)]

    Changes of participants functional independencies of performing a task over three weeks training. The FIM is a 18-item self-report instrument designed to measure participants functional independency. Items are divided into motor and cognitive categories, are classified based on the type of task it involves and are scored on a 7-point likert scale. Higher scores indicate more independencies a person has at performing the task. The score is a value ranging between 18 and 126 (total score) and is further broken down based on its motor and cognitive components. The motor component ranges from 13 to 91, while the cognitive component ranges between 5 to 35.

  3. EuroQoL-Group five dimension quality of life questionnaire (EQ-5D) [Three weeks (Day 0 - Day 21)]

    Changes of participant's health state over three weeks training with higher scores indicating a better health status.EQ-5D comprises the five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is expressed with the levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by scoring the most appropriate statement for each dimension. This decision results into a 1-digit number that expresses the level selected for the respective dimension. The digits for the five dimensions are combined into a 5-digit number.

  4. Six Minute Walking Test (6MWT) [Three weeks (Day 0 - Day 21)]

    Changes of walking speed and distance covered after in 6-Minutes over three weeks training. The greater the distance covered after six minutes the higher the walking speed.

  5. Timed-Up-and-Go (TUG) [Three weeks (Day 0 - Day 21)]

    Changes of mobility and risk of falling over three weeks training. The TUG measures the time for the participant to stand from a chair, walk three meters and sit down again. Time stops when the participants is seated. Cut-off for risk of falling is set for dwelling adults at 13.5 and for vestibular disorders at 11.1 seconds.

  6. Hospital Anxiety and Depression Scale (HADS) [Three weeks (Day 0 - Day 21)]

    Changes of anxiety and depression over three weeks training on a 4-point likert scale scored 0-3. Max 21 Points for each subscale, cut off for anxiety and Depression are set at 7 points with higher values representing more anxiety and depressive symptoms symptoms

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed with "Cancer";

  • Literacy and understanding German language;

  • Signed informed consent;

Exclusion Criteria:
  • Women who are pregnant or breastfeeding / have the intention to become pregnant during the course of the study;

  • Other clinically significant concomitant disease states (e.g. renal failure, hepatic dysfunction, cardiovascular disease, etc);

  • Known or suspected non-compliance, drug or alcohol abuse;

  • Inability to follow the procedures of the study: e.g. due to language problems, psychological disorders, dementia of the participant, etc;

  • Enrolment of the investigator, his/her family members, employees and other dependent persons;

  • Cognitive impairment: Mini-Mental State Examination (MMSE) < 21;

  • Major Depression or Hospital Anxiety and Depression Scale (HADS) >11 at baseline.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kliniken-Valens Valens Sankt Gallen Switzerland 7317

Sponsors and Collaborators

  • Klinik Valens

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jens Bansi, Head of Research and Development, Klinik Valens
ClinicalTrials.gov Identifier:
NCT04842214
Other Study ID Numbers:
  • Bansi-2021
First Posted:
Apr 13, 2021
Last Update Posted:
May 20, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Jens Bansi, Head of Research and Development, Klinik Valens
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 20, 2021